LXRX•benzinga•
Lexicon Pharmaceuticals Enters Exclusive License Agreement With Novo Nordisk For LX9851, Potentially Worth Up To $1B In Milestone Payments; Company Sees Upfront And Near-term Milestone Payments Of Up To $75M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga